Genesis Healthcare (GEN) Stock Price, News & Analysis

Company Overview

Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services; Rehabilitation Therapy Services; and Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of December 31, 2020, it provided inpatient services through a network of approximately 341 skilled nursing facilities and assisted/senior living communities in 24 states; and supplied rehabilitation and respiratory therapy to approximately 1,400 healthcare locations in 42 states, the District of Columbia and China. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.

Key Stats

• Today's Range: $29.34 to $29.91
• 50-Day Range: $0.18 to $0.60
• 52-Week Range: $0.40 to $1.37
• Volume: 3.89 million shs
• Average Volume: 4.10 million shs
• Market Capitalization: $18.76 billion
• P/E Ratio: 32.62
• Dividend Yield: 1.70%
• Price Target: $33.25
• Consensus Rating: Moderate Buy

Genesis Healthcare Stock Analysis - MarketRank™

Genesis Healthcare scored higher than 27% of companies evaluated by MarketBeat, and ranked 721st out of 894 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Genesis Healthcare has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Genesis Healthcare has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 5.52%

Earnings Growth

Earnings for Genesis Healthcare are expected to grow by 5.52% in the coming year, from $1.63 to $1.72 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Genesis Healthcare is 32.62, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.62.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genesis Healthcare is 32.62, which means that it is trading at a more expensive P/E ratio than the Business Services sector average P/E ratio of about 27.48.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GEN.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Genesis Healthcare pays a meaningful dividend of 3.05%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Genesis Healthcare does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Genesis Healthcare is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Genesis Healthcare will have a dividend payout ratio of 29.07% next year. This indicates that Genesis Healthcare will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for GEN.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

7 people have searched for GEN on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genesis Healthcare insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.30% of the stock of Genesis Healthcare is held by insiders.

Percentage Held by Institutions

82.08% of the stock of Genesis Healthcare is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GEN Stock Analysis - Frequently Asked Questions

How were Genesis Healthcare's earnings last quarter?

Genesis Healthcare, Inc. (NYSE:GEN) posted its quarterly earnings results on Thursday, August, 1st. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.53. The company's quarterly revenue was up 2.3% compared to the same quarter last year.

Is Genesis Healthcare doing a stock buyback?

Genesis Healthcare's board initiated a stock buyback plan on Thursday, May 9th 2024, which permits the company to repurchase $3,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 23.1% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board believes its shares are undervalued.

What other stocks do shareholders of Genesis Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genesis Healthcare investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/01/2024
• Today: 6/20/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Business Services
• Industry: Prepackaged software
• Sub-Industry: N/A
• Current Symbol: NYSE:GEN
• Previous Symbol: NYSE:SKH
• CIK: 849399
• Web: www.genesishcc.com
• Phone: 610-444-6350
• Fax: 302-636-5454
• Employees: 2,700
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $33.25
• High Stock Price Target: $37.00
• Low Stock Price Target: $30.00
• Potential Upside/Downside: +13.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.90
• Trailing P/E Ratio: 32.62
• Forward P/E Ratio: 18.01
• P/E Growth: N/A
• Net Income: $836 million
• Net Margins: 17.83%
• Pretax Margin: 23.69%
• Return on Equity: 155.48%
• Return on Assets: 9.12%

Debt

• Debt-to-Equity Ratio: 7.50
• Current Ratio: 0.48
• Quick Ratio: 0.48

Sales & Book Value

• Annual Sales: $2.80 billion
• Price / Sales: 6.71
• Cash Flow: $3.49 per share
• Price / Cash Flow: 8.42
• Book Value: ($0.16) per share
• Price / Book: -183.50

Miscellaneous

• Outstanding Shares: 639,130,000
• Free Float: 618,038,000
• Market Cap: $18.76 billion
• Optionable: Optionable
• Beta: 0.84